Pharmacodynamic system analysis of the biophase level predictor and the transduction function
- PMID: 1432642
- DOI: 10.1002/jps.2600810918
Pharmacodynamic system analysis of the biophase level predictor and the transduction function
Abstract
This work deals with the pharmacodynamic problem of relating a drug effect E(t) to an observable pharmacokinetic (PK) predictor variable r(t), which may be a venous and/or arterial drug level, some other PK variable, or a drug infusion scheme. It is proposed that the relationship between E(t) and r(t) may, in many cases, be appropriately modeled as E(t) = N(F(r(t))) [for practical analysis reasons, F(r(t)) is denoted the biophase level, cb(t), the operator F() is accordingly denoted the biophase level predictor (BLP), and N() is denoted the transduction function (TF)]. This work proposes a method for determining the two fundamental components, BLP and TF, that define the E(t)-r(t) relationship. The BLP is determined by a hysteresis minimization (HM) technique with the following features: (1) the method considers errors in both HM variables; (2) the method is suitable for dealing with the important case in which the predictor variable is a drug infusion scheme; (3) the approach is noncompartmental in contrast to the effect-compartment approaches and it does not require a specific structured modeling of the cb(t)-r(t) relationship when dealing with drugs with linear PKs in a general operational sense; and (4) the method makes use of a dimensionless transformation of the hysteresis variable that eliminates numerical scaling problems so that a complex penalty function optimization approach can be avoided. The TF is determined by a cross validation procedure in conjunction with the BLP determined by HM. The method is demonstrated using pharmacodynamic data for several drugs, considering both concentration-based and drug input-based r(t) values. The significance of the information obtained from the determined BLP and TF is discussed, including the concepts of equilibration dynamics and overloading. The limitations and potential problems of the methodology are discussed.
Similar articles
-
Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil.Pharm Res. 1994 Jan;11(1):128-35. doi: 10.1023/a:1018966232183. Pharm Res. 1994. PMID: 8140044
-
Application of a variable direction hysteresis minimization approach in describing the central nervous system pharmacodynamic effects of alfentanil in rabbits.J Pharm Sci. 1994 Mar;83(3):351-6. doi: 10.1002/jps.2600830317. J Pharm Sci. 1994. PMID: 8207680
-
A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling.J Pharm Sci. 1991 May;80(5):488-95. doi: 10.1002/jps.2600800518. J Pharm Sci. 1991. PMID: 1880731
-
Methodological issues in pharmacokinetic-pharmacodynamic modelling.Clin Pharmacokinet. 1998 Aug;35(2):151-66. doi: 10.2165/00003088-199835020-00004. Clin Pharmacokinet. 1998. PMID: 9739481 Review.
-
Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives.Eur J Drug Metab Pharmacokinet. 1993 Jan-Mar;18(1):41-7. doi: 10.1007/BF03220007. Eur J Drug Metab Pharmacokinet. 1993. PMID: 8335038 Review.
Cited by
-
New mathematical implementation of generalized pharmacodynamic models: method and clinical evaluation.J Pharmacokinet Biopharm. 1997 Jun;25(3):313-48. doi: 10.1023/a:1025723725312. J Pharmacokinet Biopharm. 1997. PMID: 9474531 Clinical Trial.
-
Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil.Pharm Res. 1994 Jan;11(1):128-35. doi: 10.1023/a:1018966232183. Pharm Res. 1994. PMID: 8140044
-
The use of multiple doses and pharmacodynamic system analysis to distinguish between dispositional delays and time-variant pharmacodynamics.Pharm Res. 1994 Dec;11(12):1825-8. doi: 10.1023/a:1018940122382. Pharm Res. 1994. PMID: 7899250
-
A 'bottom-up' approach for endo-PK/PD analysis.Biopharm Drug Dispos. 2006 Oct;27(7):313-27. doi: 10.1002/bdd.508. Biopharm Drug Dispos. 2006. PMID: 16892181 Free PMC article.
-
Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.Clin Pharmacokinet. 1997 Apr;32(4):259-67. doi: 10.2165/00003088-199732040-00001. Clin Pharmacokinet. 1997. PMID: 9113436 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous